JP2013523652A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523652A5
JP2013523652A5 JP2013501501A JP2013501501A JP2013523652A5 JP 2013523652 A5 JP2013523652 A5 JP 2013523652A5 JP 2013501501 A JP2013501501 A JP 2013501501A JP 2013501501 A JP2013501501 A JP 2013501501A JP 2013523652 A5 JP2013523652 A5 JP 2013523652A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
alkyl
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501501A
Other languages
English (en)
Japanese (ja)
Other versions
JP6065183B2 (ja
JP2013523652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029879 external-priority patent/WO2011119894A2/en
Publication of JP2013523652A publication Critical patent/JP2013523652A/ja
Publication of JP2013523652A5 publication Critical patent/JP2013523652A5/ja
Application granted granted Critical
Publication of JP6065183B2 publication Critical patent/JP6065183B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501501A 2010-03-24 2011-03-24 キナーゼ阻害に役立つ複素環式化合物 Expired - Fee Related JP6065183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31722310P 2010-03-24 2010-03-24
US61/317,223 2010-03-24
PCT/US2011/029879 WO2011119894A2 (en) 2010-03-24 2011-03-24 Heterocyclic compounds useful for kinase inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016236174A Division JP6391126B2 (ja) 2010-03-24 2016-12-05 キナーゼ阻害に役立つ複素環式化合物

Publications (3)

Publication Number Publication Date
JP2013523652A JP2013523652A (ja) 2013-06-17
JP2013523652A5 true JP2013523652A5 (cg-RX-API-DMAC7.html) 2014-05-15
JP6065183B2 JP6065183B2 (ja) 2017-01-25

Family

ID=44673873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013501501A Expired - Fee Related JP6065183B2 (ja) 2010-03-24 2011-03-24 キナーゼ阻害に役立つ複素環式化合物
JP2016236174A Expired - Fee Related JP6391126B2 (ja) 2010-03-24 2016-12-05 キナーゼ阻害に役立つ複素環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016236174A Expired - Fee Related JP6391126B2 (ja) 2010-03-24 2016-12-05 キナーゼ阻害に役立つ複素環式化合物

Country Status (12)

Country Link
US (3) US8957216B2 (cg-RX-API-DMAC7.html)
EP (1) EP2550266B1 (cg-RX-API-DMAC7.html)
JP (2) JP6065183B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180032686A (cg-RX-API-DMAC7.html)
CN (1) CN102884060B (cg-RX-API-DMAC7.html)
AU (2) AU2011232372B2 (cg-RX-API-DMAC7.html)
CA (1) CA2794086A1 (cg-RX-API-DMAC7.html)
ES (1) ES2677356T3 (cg-RX-API-DMAC7.html)
IL (1) IL222068B (cg-RX-API-DMAC7.html)
MX (2) MX345552B (cg-RX-API-DMAC7.html)
RU (2) RU2640862C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011119894A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011097594A2 (en) * 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US8957216B2 (en) * 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
NZ604831A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
EP3495367B1 (en) 2012-06-13 2020-09-30 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134404A1 (en) * 2014-04-25 2017-03-01 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
US10238636B2 (en) 2014-09-24 2019-03-26 Gilead Sciences, Inc. Methods of treating liver disease
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
BR112017013382A2 (pt) 2014-12-23 2018-02-14 Gilead Sciences Inc método para preparar um composto, composto, e, ácido.
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016161952A1 (zh) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN108191781B (zh) * 2018-01-08 2020-01-21 浙江大学 取代三氮唑类衍生物及其在制备抗肿瘤转移药物中的应用
GB201801226D0 (en) * 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CN108864060A (zh) * 2018-06-03 2018-11-23 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108610336A (zh) * 2018-06-03 2018-10-02 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108586439A (zh) * 2018-06-03 2018-09-28 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115916966A (zh) * 2020-01-30 2023-04-04 加利福尼亚大学董事会 Strad结合剂及其用途
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023222849A1 (en) * 2022-05-19 2023-11-23 Astrazeneca Ab Amino heteroaromatic compounds useful in the treatment of liver diseases
KR20250016177A (ko) 2022-05-19 2025-02-03 아스트라제네카 아베 간 질환의 치료에 유용한 아미도 헤테로방향족 화합물

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4031893A (en) 1976-05-14 1977-06-28 Survival Technology, Inc. Hypodermic injection device having means for varying the medicament capacity thereof
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5358489A (en) 1993-05-27 1994-10-25 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
US5695472A (en) 1993-05-27 1997-12-09 Washington Biotech Corporation Modular automatic or manual emergency medicine injection system
US5540664A (en) 1993-05-27 1996-07-30 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
US5962685A (en) 1994-08-02 1999-10-05 Nippon Soda Co., Ltd. Oxazole derivatives, process for producing the same, and herbicide
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7544189B2 (en) 2000-10-10 2009-06-09 Meridian Medical Technologies, Inc. Needle and hub assembly for automatic injector
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
MX2007002177A (es) * 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
US7754747B2 (en) * 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
JP5275628B2 (ja) * 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
CN101654452A (zh) * 2004-08-25 2010-02-24 塔尔基公司 杂环化合物和应用方法
CN101111489A (zh) * 2005-02-01 2008-01-23 惠氏公司 作为β-分泌酶的抑制剂的氨基-吡啶
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US7932390B2 (en) * 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
WO2008093677A1 (ja) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
RU2497811C2 (ru) * 2009-02-04 2013-11-10 Оцука Фармасьютикал Фэктори, Инк. Фенилимидазольные соединения
WO2011097594A2 (en) * 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition

Similar Documents

Publication Publication Date Title
JP2013523652A5 (cg-RX-API-DMAC7.html)
RU2012144751A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2016503797A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2015511217A5 (cg-RX-API-DMAC7.html)
RU2016119519A (ru) Соединения гетероарила в качестве ингибиторов btk и их применение
JP2015511638A5 (cg-RX-API-DMAC7.html)
JP2017528498A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
CY1118340T1 (el) Αναστολεις κινασης
JP2016530283A5 (cg-RX-API-DMAC7.html)
JP2018511631A5 (cg-RX-API-DMAC7.html)
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
JP2018522866A5 (cg-RX-API-DMAC7.html)
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2012522729A5 (cg-RX-API-DMAC7.html)
JP2016506387A5 (cg-RX-API-DMAC7.html)
JP2017507122A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
RU2012138579A (ru) Производные пиримидина и их применение в лечении респираторных заболеваний, таких как copd
JP2014512364A5 (cg-RX-API-DMAC7.html)